8 June 2015: Motiv Bio CEO tells IG that while AIM, the alternative investment market, is better understanding value in biotech stocks, a Nasdaq listing is an option for the company. This, Mr Lumsdan says, should help boost the company’s valuation.
8 June 2015: Motiv Bio CEO tells IG that while AIM, the alternative investment market, is better understanding value in biotech stocks, a Nasdaq listing is an option for the company. This, Mr Lumsdan says, should help boost the company’s valuation.
Related Posts: